IBI3027

DRUG2 trials

Sponsors

Innovent Biologics (Suzhou) Co. Ltd.

Conditions

Atopic DermatitisHealthy Volunteers

Phase 1

A Clinical Study Comparing the Bioequivalence of IBI3027 and DUPIXENT®(Dupilumab) in Healthy Chinese Volunteers

Active, not recruitingNCT07502534

Innovent Biologics (Suzhou) Co. Ltd.Healthy Volunteers

Start: 2026-04-24End: 2026-07-07Updated: 2026-05-15

Phase 3

A Study to Evaluate the Equivalence of IBI3027 and Dupilumab Injection in Participants With Moderate to Severe Atopic Dermatitis

Not yet recruitingNCT07754786

Innovent Biologics (Suzhou) Co. Ltd.Atopic Dermatitis

Start: 2026-10-20End: 2028-08-26Target: 520Updated: 2026-08-10